← All trials
NCT01173809
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2010
- Primary completion
- May 1, 2014
- Completion date
- Jul 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 176
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Texas Cardiac Arrhythmia InstituteLead sponsor
- Texas Cardiac Arrhythmia InstituteOverall official - principal investigator
- TCAI, St.David's Medical CenterOverall official - principal investigator
- Stanford UniversityCollaborator
- Case Western Reserve UniversityCollaborator
- Southlake Regional Health CentreCollaborator
- University of California, San FranciscoCollaborator
- Texas Cardiac Arrhythmia InstituteReponsible party - principal investigator
- University of KansasCollaborator
- Catholic University of Sacred Heart, RomeCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.